The current research explored for the first time the effect of Salvia officinalis L. (Sage) essential oil (EO) on Alloxan-induced diabetes in male Wistar rats. Sage EO was extracted by a Clevenger apparatus and analyzed by GC-FID and GC-MS. The most important chemical families identified in this oil were oxygenated monoterpenes (56.32%), hydrocarbon monoterpenes (15.00%) and hydrocarbon sesquiterpenes (14.70%). All treatments were administered orally. In vitro investigation showed that the EO had α-amylase and lipase inhibitory activities with IC50 = 38 μg/mL and IC50 = 52 μg/mL, respectively. In vivo experiments highlighted that the activities of serum α-amylase and lipase were reduced by 46.6% and 32.1%, respectively. Sage EO reduced glycemia by 60% and the level of glycogen stored in the liver by 43.7%. Treatments of diabetes with Sage EO significantly protected the liver function by lowering serum AST (35%), ALT (79%) and LDH (43%) activities. Furthermore, Sage EO was efficient to preserve the kidney function in diabetes by reverting back serum creatinine (47%) and UA (62.5%) concentrations to control values. The obtained results altogether evidenced that Sage EO had hypoglycemic and anti-obesity effects and could be a valuable complement in future diabetes therapy.
Keywords: Essential oil; Glycemia; Monoterpenes; Rat digestive key enzymes; Salvia officinalis lamiaceae.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.